GlassScriptPhysician profile
Robin M Moore
NPI 1770559270
$7,830.77
in general payments reported to CMS, 2019-2025
48 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $746 · 2021: $1,128 · 2022: $1,395 · 2023: $1,060 · 2024: $1,085 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,330 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.53 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,509.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,123.52 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $592.22 | 2019-2024 | |
| Lilly USA, LLC | $517.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Inspire Medical Systems, INC. | $358.43 | 2023-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $341.87 | 2019-2023 | Trintellix |
| Exact Sciences Corporation | $233.87 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $213.08 | 2019-2022 | |
| Amarin Pharma, INC. | $211.96 | 2019-2022 | |
| Pfizer INC. | $209.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.33 | 2019-2022 | |
| Redhill Biopharma INC. | $143.69 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $130.81 | 2022-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $130.54 | 2019-2020 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $120.18 | 2022 | |
| Nevro Corp. | $116.67 | 2020 | |
| Merck Sharp & Dohme LLC | $111.48 | 2019 | |
| Amgen INC. | $106.86 | 2019-2025 | Repatha, Otezla |
| Astellas Pharma US INC | $96.62 | 2023-2024 | Veozah |
| Currax Pharmaceuticals LLC | $92.97 | 2023-2024 | Contrave, Nexletol, Onzetra Xsail |
| Allergan, INC. | $89.53 | 2019-2021 | |
| Dexcom, INC. | $86.54 | 2024-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $84.12 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biohaven Pharmaceutical Holding Company LTD. | $83.47 | 2022 | |
| Optinose US, INC. | $65.82 | 2019 | |
| Viiv Healthcare Company | $62.13 | 2025 | Apretude |
| Ironshore Pharmaceuticals INC. | $59.25 | 2019 | |
| Scilex Pharmaceuticals INC. | $52.19 | 2019 | |
| Glaxosmithkline, LLC. | $49.86 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $43.29 | 2025 | |
| Arbor Pharmaceuticals, INC. | $42.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $39.60 | 2019-2022 | |
| Shire North American Group INC | $38.77 | 2019 | |
| Emd Serono, INC. | $38.27 | 2024-2025 | |
| Genentech USA, INC. | $36.47 | 2019-2022 | |
| Ethicon US, LLC | $32.52 | 2021-2022 | |
| Boston Scientific Corporation | $27.08 | 2023 | Watchman Access System |
| Biohaven Pharmaceuticals, INC. | $24.24 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.11 | 2023 | Quviviq |
| Ibsa Pharma INC. | $20.97 | 2024 | Licart, Tirosint |
| Titan Spine, LLC | $20.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.48 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.28 | 2025 | Azmiro |
| Noven Therapeutics, LLC | $17.22 | 2023 | Secuado |
| Vivus LLC | $17.04 | 2019 | |
| Adlon Therapeutics L.P. | $15.75 | 2021 | |
| Horizon Therapeutics Plc | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.